Immunomodulatory gene therapy for haematological malignancies

Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.

Cancer immunology, immunotherapy : CII·2020

Cross-sectional increase of adherence to multidisciplinary tumor board decisions.

BMC cancer·2018

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.

Leukemia·2015

[State of the art treatment of progressive or refractory multiple myeloma].

Deutsche medizinische Wochenschrift (1946)·2014

Hairy cell leukemia: short review, today's recommendations and outlook.

Blood cancer journal·2014

Wnt/ß-catenin: a new therapeutic approach to acute myeloid leukemia.

Leukemia research and treatment·2012

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.

British journal of haematology·2026

Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy.

British journal of haematology·2026

Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial.

British journal of haematology·2026

Trends and socio-economic disparities in chronic lymphocytic leukaemia 2014-2022: An England-wide cohort study from the UNCOVER group.

British journal of haematology·2026

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.

British journal of haematology·2026

Diagnosis and monitoring of thrombotic thrombocytopenic purpura: Guidance for laboratories from the British Society for Haematology.

British journal of haematology·2026

Blinatumomab administration in the outpatient setting: Safety and health care utilization.

Cancer·2026

Subcutaneous versus intravenous ultra-low dose rituximab in rheumatoid arthritis: a randomised controlled PK-PD non-inferiority trial.

Rheumatology (Oxford, England)·2026

The Role of γδ T Cells in Ischemic Stroke: Insights From the Perspective of the Brain-Gut Axis.

CNS neuroscience & therapeutics·2026

Macrophage migration inhibitory factor promotes immune evasion in multiple myeloma through myeloid-derived suppressor cell immunosuppression and major histocompatibility complex class I downregulation: implications for targeted therapy.

Haematologica·2026

Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications.

Haematologica·2026

Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin's lymphoma and FDG-PET positivity after 2 cycles of ABVD: final analysis of the BRAPP2 trial.

Haematologica·2026

Related Experiment Videos

Immunomodulatory gene therapy for haematological malignancies

Related Concept Videos

Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.

Cross-sectional increase of adherence to multidisciplinary tumor board decisions.

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.

[State of the art treatment of progressive or refractory multiple myeloma].

Hairy cell leukemia: short review, today's recommendations and outlook.

Wnt/ß-catenin: a new therapeutic approach to acute myeloid leukemia.

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.

Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy.

Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial.

Trends and socio-economic disparities in chronic lymphocytic leukaemia 2014-2022: An England-wide cohort study from the UNCOVER group.

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.

Diagnosis and monitoring of thrombotic thrombocytopenic purpura: Guidance for laboratories from the British Society for Haematology.

Blinatumomab administration in the outpatient setting: Safety and health care utilization.

Subcutaneous versus intravenous ultra-low dose rituximab in rheumatoid arthritis: a randomised controlled PK-PD non-inferiority trial.

The Role of γδ T Cells in Ischemic Stroke: Insights From the Perspective of the Brain-Gut Axis.

Macrophage migration inhibitory factor promotes immune evasion in multiple myeloma through myeloid-derived suppressor cell immunosuppression and major histocompatibility complex class I downregulation: implications for targeted therapy.

Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications.

Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin's lymphoma and FDG-PET positivity after 2 cycles of ABVD: final analysis of the BRAPP2 trial.

Related Experiment Videos

Immunomodulatory gene therapy for haematological malignancies

Related Concept Videos

Related Articles